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This study aims to investigate associations between ob-
served clinical parameters and known genetic risk fac-
tors of psoriasis in a well-defined prospective cohort of 
paediatric patients with plaque psoriasis (n = 151). Signi-
ficant associations were found for paediatric-onset pso-
riasis with ERAP1 (p = 0.002), IL23R (p = 0.01), LCE3C_
LCE3B-del (p = 0.00049) and HLA-C*06 (p = 3.15 × 10–30). 
Psoriasis severity was associated with the single nucleoti-
de polymorphisms tagging IFIH1 and ERAP1 (p < 0.05). 
An onset before 10 years of age was associated with 
IL12B (p = 0.02). Nail psoriasis was more often seen in 
HLA-C*06-negative patients (p = 0.008). Remarkably, fa-
mily history is clearly not associated with HLA-C*06 in 
this specific group. The large proportion of patients with 
a positive family history in HLA-C*06 negative patients 
(and the lack of correlation between the two) indicates 
that other genes, either alone or interaction between two 
or more genes, may have significant effects on heritabili-
ty. Key words: genotype-phenotype correlations; paediatric 
psoriasis; genetic risk factors; clinical parameters.
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Psoriasis is a clinically heterogeneous skin disease with a 
complex genetic background (1–3). It affects around 2% of 
the population and in approximately 30% of these patients 
the disease first appears during childhood (1, 4). By means 
of genome-wide association studies, the number of genome 
regions identified to be associated with psoriasis increased 
recently to 36 (5). Different pathways evidently play a 
role in the pathophysiology of psoriasis, as the innate and 
adaptive immune system, the Th17 pathway and the skin 
barrier function are genetically linked with psoriasis (2, 3, 
6–13). Some studies have investigated correlations between 
genetic risk factors of psoriasis and clinical parameters, 
and these were mainly focused on major histocompatibi-
lity (MHC) gene HLA-C*06 (14–23). In a cohort of adult 
psoriasis patients a strong association was demonstrated 
between psoriasis severity and single nucleotide polymor-
phisms (SNPs) tagging HLA-C*06 and a deletion of LCE3B 
and LCE3C (22, 34). Several studies have shown that early 
age at onset may be associated with distinct genetic factors, 
such as ERAP1 and HLA-C*06 (14, 17, 23, 24). Previous 
studies detected an association between HLA-C*06 and 
early onset psoriasis (onset < 30 or 40 years), and a positive 
family history of psoriasis and early onset of psoriasis (14, 
16, 17, 20), suggesting an association between HLA-C*06 
and family history of psoriasis in patients with early onset 
psoriasis. This association has however, never been investi-
gated. Data about associations between clinical parameters 
and genetic risk factors in paediatric psoriasis are lacking. 
The current study aims to investigate associations between 
observed clinical parameters and known genetic risk factors 
of psoriasis in a well-defined cohort of paediatric patients 
with plaque psoriasis. 
MATERIALS AND METHODS
Sample collection
DNA samples were obtained from children with psoriasis refer-
red to the outpatient clinic of the Department of Dermatology 
of the Radboud University Medical Center. Only patients of 
European descent with a primary diagnosis of plaque-type pso-
riasis, before the age of 18 years, were included in this study. 
Patients with guttate psoriasis were excluded. The phenotype 
classification is based on phenotype at examination and not at 
onset of disease. We obtained clinical data from our prospec-
tive observational paediatric psoriasis registry in daily clinical 
practice, called Child-CAPTURE (Continuous Assessment of 
Psoriasis Treatment Use Registry). In this registry, patient cha-
racteristics including age at onset, family history of psoriasis 
(up to the third-degree relative) and Koebner phenomenon are 
recorded at the first visit. Psoriasis severity and presence of 
observed nail psoriasis by the physician are recorded every visit. 
The characteristics of the control group of European descent 
were previously described (24). Only self-reported data were 
available for all controls, and individuals reported to have pso-
riasis were excluded from this study. All participants/parents 
gave written informed consent. 
Genotyping
Genotyping was executed as previously described (24). In 
short, SNP genotyping was performed using Taqman® SNP 
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genotyping assays (assay IDs C_920306_20, C_1272298_10, 
C_3056837_10, C_34244955_10, and C_29927086, for SNPs 
rs240993, rs11209026, rs27524, rs17716942, and rs3213094, 
respectively) according to the manufacturer’s recommendations 
(Applied Biosystems, Nieuwerkerk aan den IJssel, The Nether-
lands). LCE3C_LCE3B-del genotyping was performed using a 
previous described PCR (2). HLA-C*06:02 itself (rather than a 
tagging SNP) was determined by PCR with sequence specific 
primers for C*06 (2), which does not allow distinction between 
homozygotes and heterozygotes. As quality control on the SNP 
typing 5% of the samples were analysed in duplicate; all ge-
notypes were concordant. The SNPs, LCE3C_LCE3B-del and 
HLA-C*06:02 were successfully genotyped in the psoriasis and 
control samples with genotyping success rates between 97.9% 
and 99.7%, 99.1% and 95.8%, respectively. for SNP genoty-
ping, genotype cluster plots were evaluated prior to analysis to 
ensure satisfactory assay performance. 
Statistical analysis
No deviations from Hardy-Weinberg equilibrium were found in 
the control groups. Logistic regression analyses were performed 
in SPSS software 20.0 (SPSS Inc., Chicago, IL, U.S.A.) using 
co-dominant models. The odds ratio (OR) and 95% confidence 
interval (CI) were calculated using homozygosity for the non-
risk variant (from previous studies) as a reference for the case-
control study. Age at onset was analysed comparing 2 groups; 
before 10 years and at or after 10 years. Clinical severity of 
psoriasis was assessed by a clinician using 3 different severity 
scales: Psoriasis Area and Severity Index (PASI; range 0–72), 
Physician Global Assessment (PGA; range 0–5) and Body 
Surface Area (BSA; range 0–100) (25). The highest reported 
psoriasis severity scores for each individual were used. Patients 
were divided in 2 groups based on psoriasis severity scores; 
mild-to-moderate and severe psoriasis. Mild-to-moderate pso-
riasis was defined as those patients that have never reached 
PASI ≥ 10, PGA ≥ 3 or BSA ≥ 10. Severe psoriasis was defined 
as those patients that have ever reached PASI ≥ 10, PGA ≥ 3 or 
BSA ≥ 10. Nail psoriasis was scored by using the Nail Psoriasis 
Severity Index (NAPSI; range 0–80) (26). Koebner phenomenon 
was assessed based on a 4-point scale, how often a psoriasis 
plaque appeared after skin damage of their non-involved skin: 
never, rarely, often, or very common. The individuals who re-
sponded with ‘‘often’’ or ‘‘very common’’ were considered as 
Koebner-positive patients and the others as Koebner-negative 
patients, which is in line with our previous study (27). To test 
for the association with psoriasis clinical variables, chi-square 
tests were executed from the allele frequency table (2 × 2 tables). 
Logistic regression analyses were performed to calculate ORs 
and 95% CIs. The level of significance was considered to be 
0.05. Power calculations were performed using the Genetic 
Power calculator (28).
RESULTS
Cohort characteristics
The investigated cohort for the replication of the asso-
ciations between paediatric-onset psoriasis and healthy 
controls consisted of 151 cases and 450 controls, which 
is a doubling of the number of cases compared to our 
previous study (24). The power to detect an association 
ranged between 18% and 100%. Patient cohort charac-
teristics are reported in Table I. A female preponderance 
was found (59%) in the cases, which was also present 
in the control group (60.9%) (24). for a total of 139 
psoriasis patients clinical data were available from 
our Child-CAPTURE registry (see below). We found 
no significant phenotype differences between patients 
with an age at onset < 10 years and ≥ 10 years.
Replication of genetic associations with paediatric-
onset psoriasis
Logistic regression analysis of our extended cohort 
demonstrated the same associations with 4 of the 7 
tested loci as in our previous study (24), albeit this 
time with increased significance. The 4 genes were 
IL23R (OR 2.42, 95% CI 1.23–4.74, ERAP1 (OR 1.55, 
95% CI 1.18–2.03), LCE3B_LCE3C-del (OR 1.67, 
95% CI 1.25–2.22, and HLA-C*06 (OR 17.1, 95% CI 
10.5–27.9) (Table II).
Associations with clinical psoriasis characteristics 
Age at onset of psoriasis. The mean age ± SD at onset of 
psoriasis in our cohort was 8.2 ± 4.1 years. The group of 
children with an early onset  (< 10 years; n = 86) had a 
mean age at onset of 5.5 ± 2.2 years, and the other group 
(≥ 10 years; n = 53) had a mean age at onset of 12.7 ± 2.0 
years. for IL12B, analysed using SNP rs3213094, we 
demonstrated a significant association between age at 
onset < 10 years and the risk (T) allele, with an OR of 
2.59 (95% CI 1.14–5.88, p = 0.02); 17% of patients 
with an age at onset < 10 years carried this risk allele, 
compared to 7.5% of the patients with an age at onset 
≥ 10 years (Table III). None of the other analysed loci 
showed significant associations.
Family history of psoriasis. In 38.1% (n = 53) of the 
patients a first-degree relative stated to have psoriasis. 
Two thirds of the patients (67.6%, n = 94) reported a 
positive family history of psoriasis up to third degree 
relatives. However, we found no significant associations 
between family history of psoriasis (first and up to third 
degree relatives) and the allele frequency of the psoriasis 
Table I. Patient cohort characteristics
Cohort characteristics
Number of cases 151
Male, n (%) 57 (41.0)
Age, years, mean ± SD (range)a 13.0 ± 4.1 (4–18)
Psoriasis characteristics a
Age at onset of psoriasis, years, mean ± SD (range) 8.2 ± 4.1 (0–17)
Duration of psoriasis, months, mean ± SD (range) 32.9 ± 35.9 (1–154)
Time of follow-up, months, mean ± SD (range) 17.8 ± 15.4 (0–54)
family history of psoriasis, n (%)
first-degree relatives 53 (38.1)
Up to the third degree relatives 94 (67.6)
Severe psoriasis, n (%) 77 (55.4)
Nail involvement, n (%) 40 (28.8)
Koebner-positive patients, n (%) 43 (30.9)
aData were available for 139 subjects.
SD: standard deviation.
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risk factors. Remarkably, even HLA-C*06 showed no 
significant association with family history of psoriasis 
(first degree relatives p = 0.92 and up to third degree 
relatives p = 0.76). In patients with a positive family his-
tory up to third degree relatives 76.1% were HLA-C*06 
positive and in patients with only first-degree relatives 
with psoriasis, 76.5% were HLA-C*06 positive. In pa-
tients with a negative family history up to third degree 
relatives, 78.6% were HLA-C*06-positive compared 
to 77.2% in patients with no first-degree relatives with 
psoriasis (Table IV). 
Psoriasis severity. In our cohort 55.4% (n = 77) of 
the patients were classified as having severe pso-
riasis. Significant associations were demonstrated 
between severe psoriasis and the risk (T) allele of 
SNP rs17716942 (IFIH1) with an OR of 2.41 (95% 
CI 1.14–5.12, p = 0.019) and the risk (A) allele of 
SNP rs27524 (ERAP1, OR 1.64, 95% CI 1.01–2.67, 
p = 0.047) (Table III). 
Nail involvement. In HLA-C*06 negative patients we 
found a significant increase of nail involvement (OR 
0.32, 95% CI 0.14–0.76, p = 0.008, Table III). None 
of the other psoriasis risk alleles showed a positive or 
negative association with this clinical parameter. 
Koebner-phenomenon. forty-three patients (30.9%) 
were Koebner-positive. None of the investigated risk 
factors showed a significant association with Koebne-
rization in our cohort. 
DISCUSSION
This is the first study to report associations between 
clinical parameters and genetic risk factors in a prospec-
tive paediatric psoriasis cohort. We could confirm and 
strengthen, in a larger patient group, our previous findings 
that paediatric-onset psoriasis is associated with HLA-
C*06, LCE3C_LCE3B deletion and SNPs in the ERAP1 
and IL23R loci (24). We performed additional analyses ba-
sed on clinical data from these children and demonstrated 
that age at onset, psoriasis severity and nail psoriasis are 
associated with different genetic risk factors of psoriasis. 
Remarkably, family history of psoriasis is clearly not as-
sociated with HLA-C*06 in this specific group.
for analysis of a possible effect of age at onset, we 
divided the patients into 2 groups with a cut-off point 
at 10 years of age, which is in line with data previously 
published by Lysell et al. (23). They demonstrated, in 
a Swedish cohort, that ERAP1 showed an association, 
albeit weak, with a psoriasis onset between 10 and 20 
years. Also the strongest association with HLA-C*06 
was found for this age group. We did not, however, find 
associations between age at onset and ERAP1 and HLA-
C*06 in the Dutch paediatric psoriasis patients, which 
may be due to ethnic variation. In our cohort, an age at 
onset before 10 years was demonstrated to be associated 
with IL12B, which encodes the p40 subunit of interleukin 
(IL)-23 and IL-12 and is involved in both the IL12/Th1 
pathway and IL23/Th17 pathway of psoriasis (29, 30). 
Table II. Genetic associations with paediatric-onset psoriasis (stratified by age of onset adjusted for sex)
Single nucleotide 
polymorphism Gene Allelea
frequency of risk alleles
PTrend
Odds ratio (95% 
confidence interval)Patients Controls
rs11209026 IL23R G/A 0.97 0.92 0.010 2.42 (1.23 to 4.74)
rs3213094 IL12B T/C 0.13 0.18 0.088 0.72 (0.50 to 1.05)
rs27524 ERAP1 A/G 0.43 0.33 0.002 1.55 (1.18 to 2.03)
rs17716942 IFIH1 T/C 0.88 0.86 0.445 1.16 (0.79 to 1.72)
rs240993 TRAF3IP2 T/C 0.29 0.27 0.132 1.09 (0.82 to 1.45)
direct PCR LCE3C_LCE3B DEL/WT 0.72 0.60 0.00049 1.67 (1.25 to 2.22)
direct PCR HLA-C*06 POS/NEG 0.78 0.17 3.15E-30 17.1 (10.5 to 27.9)
aThe first allele is the allele associated with psoriasis.
DEL: deletion; WT: wild type; POS: positive; NEG: negative.
Significant p-values are shown in bold.
Table III. Significant associations between clinical characteristics and psoriasis risk factors
Gene/locus Clinical characteristics
frequency of  
risk allele
Odds ratio 
(95% confidence interval) p-value
IL12B/rs3213094 Age at onset
< 10 years 0.17 2.59 (1.14–5.88) 0.020
≥ 10 years 0.08
ERAP1/rs27524 Psoriasis severity
Mild-to-moderate psoriasis 0.36 1.64 (1.01–2.67) 0.047
Severe psoriasis 0.48
IFIH1/rs17716942 Psoriasis severity
Mild-to-moderate psoriasis 0.83 2.41 (1.14–5.12) 0.019
Severe psoriasis 0.92
HLA-C*06/direct PCR Nail involvement
yes 0.61 0.32 (0.14–0.76) 0.008
No 0.83
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Previous studies detected associations between HLA-
C*06 and early onset psoriasis, and between a positive 
family history and early onset of psoriasis in groups of 
mainly adult patients (14, 16, 17, 19). These findings 
suggest an association between HLA-C*06 and a posi-
tive family history. In our paediatric cohort, however, 
with 67.6% of the patients having a positive family 
history up to third degree relatives, including 38.1% 
with first degree relatives with psoriasis, and a total 
of 77.8% HLA-C*06 positive patients, an association 
between family history and HLA-C*06 was not found. 
This is due to the fact that similar proportions of HLA-
C*06 positivity in both the group with a positive family 
history (first degree relatives 76.5% vs up to the third 
degree relatives 76.1%) and a negative family history 
(first degree relatives 77.2% vs up to the third degree 
relatives 78.6%) were found (Table IV). Although our 
cohort is relatively small, it is highly unlikely that 
increasing the number of cases would reveal such an 
association. Previous studies reported an association of 
HLA-C*06 with type 1 psoriasis (early onset, positive 
family history) but not with type 2 (late onset, no posi-
tive family history) (14, 16). There are, however, several 
discrepancies with regard to the age criteria. Type 1 
psoriasis is variably and loosely defined, depending on 
the study, as having an onset before 30 or 40 years and 
by a positive family history. Clearly this cannot be a 
comprehensive classification as there are many patients 
with early onset and negative family history and also 
patients with adult onset that have a positive family 
history. We analysed truly paediatric patients (onset < 18 
years), which is by definition not type 2 psoriasis, but 
neither necessarily type 1 because of the requirement 
of positive family history. 
Although the lack of correlation between HLA-C*06 and 
positive family history comes somewhat as a surprise, it is 
clearly not unprecedented. Gudjonsson et al. (19), demon-
strated in a large mixed cohort of paediatric and adult-onset 
psoriasis that also many of the HLA-C*06 positive patients 
have a negative family history. Based on our own data and 
those of Gudjonsson et al. (19) we would argue that the 
historic classification of type 1 and 2 psoriasis is no longer 
meaningful. Classifications based on the presence of esta-
blished genetic risk factors are likely to be more helpful in 
future studies for personalised approaches with respect to 
prognosis and treatment. Even when age of onset is used 
as a classifier, the distinction between paediatric (< 18 
years) and adult psoriasis (≥ 18 years) is probably more 
informative than the cut-off point of age 30 or 40 years, 
which is used in early and late onset psoriasis.
The most striking clinical association in our paedia-
tric cohort with any of the genetic risk factors was the 
observation that nail psoriasis was found more often in 
HLA-C*06 negative patients (p < 0.008). This associa-
tion has been previously reported for a larger cohort 
(unstratified for age) by Gudjonsson et al. (19).
Psoriasis severity in adults was previously demonstra-
ted to be associated with HLA-C*06 and LCE3C_LCE3B 
deletion (17, 19, 20, 22). In our pediatric cohort we did 
not find these associations. We did, however, identify 
an association between psoriasis severity and IFIH1 
and ERAP1. IFIH1 encodes the interferon-induced 
with helicase C domain 1 (innate immune system), 
which triggers type I interferon in response to microbial 
infection (31), and variants are associated with type 
1 diabetes (32). ERAP1 encodes an amino peptidase, 
which regulates the quality of peptides bound to MHC 
class I molecules, such as HLA-C*06 (33). 
A limitation of this study is the modest sample size 
for genetic studies. Considering that only children were 
included, it is, however, the largest cohort described 
with clinical features. In our cohort more than 50% of 
the patients was defined as severe psoriasis which could 
introduce a selection bias. 
In conclusion, our findings suggest that genetic poly-
morphisms in both innate and adaptive immunity play 
a role in paediatric plaque psoriasis severity and age at 
onset of psoriasis. We confirm earlier associations found 
in adult psoriasis between HLA-C*06 with respect to 
nail involvement. The large proportion of patients with 
a positive family history in HLA-C*06 negative patients 
(and the lack of correlation between the two) indicates 
that other genes, either alone or interaction between 
two or more genes (34), may have significant effects 
on heritability. 
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